Catherine Auld, Director


Ms. Catherine Auld – Ms. Catherine Auld is a CPA, C.A. and has a Bachelor of Commerce from Queen's University. Ms. Auld is an experienced senior financial executive who currently serves as the Executive Director of Finance and Operations at Crescent Oral Surgery. Ms. Auld has provided CFO and other financial consulting services to public and private companies in the Biotechnology, Healthcare IT and Pharma industries for over 20 years. She has a deep understanding and expertise in public reporting, budgeting, cash flow management, contracting, treasury, human resources, corporate governance, investor relations and merger & acquisition activities. Ms. Auld served as interim CFO and consultant at Arius Research Inc., which was acquired by Roche, CFO for Transition Therapeutics Inc. and NeuroMedix Inc. and Executive Director, Finance for Optimer Pharmaceuticals. Ms. Auld started her career at KPMG LLP

Guy Chamberland, Director


Dr. Guy Chamberland, M.Sc., Ph.D., Master Herbalist, is a drug development specialist with 25 years experience in the pharmaceutical industry. Having obtained a Master’s of Science and Doctorate (PhD) degree in biomedical sciences, he has developed an expertise in drug safety and regulatory affairs while working in the pharmaceutical and biotechnology industries. He has specific expertise in the development of drug-device combination products, biologics, and botanical medicines.

Dr. Chamberland has served as Tetra Bio-Pharma’s Chief Executive Officer and Chief Regulatory Officer since October 15, 2018. He is responsible for the transformation of the biotechnology company into a pharmaceutical firm that discovers, develops and commercializes cannabinoid-based pharmaceuticals. The mandate began with a company of less than 10 employees and today has over 50 employees specialized in regulatory affairs, clinical research, manufacturing compliance, clinical trial product manufacturing, clinical operations and research and development. Dr. Chamberland oversees the scientific and regulatory requirements for drug and medical device approval (i.e., vaporizers) and strategic planning for corporate development.

Dr. Chamberland has become a thought leader in botanical medicine, publishing, lecturing and delivering continuing education workshops to health professionals on the use of plants for the treatment of pain, anxiety, insomnia, and wound healing. He is a Professor of Botanical Medicine and Principles of Clinical Research at the École d’Enseignement Supérieur de Naturopathie du Québec (EESNQ) and the French language equivalent of the Canadian College of Naturopathic Medicine (CCNNM). He earned a diploma in Proficiency in Herbal Prescription from the Australian College of Phytotherapy, and Certified Herbalist and Master Herbalist diplomas from the Dominion College of Canada. Dr. Chamberland received a B.Sc. in Agriculture form McGill University, an M.Sc. in Veterinary Anatomy and Physiology and a Ph.D. in Biomedical Sciences (toxicology) from the University of Montreal.

Dr. Chamberland is a pioneer in drug-device combination products. He developed and executed the regulatory strategy for two novel products and obtained marketing approval. In 2002, he was invited by the FDA to present at the FDA Public Hearing to regulate combination products. He spent 7-years as a member of the Scientific Advisory Committee of a Venture Capital fund and 6-years on a Health Canada Expert Committee. He was also employed by the Victhom Laboratory; Angiogene Inc.; CATO Research Ltd; and MDS Pharma, respectively.

John Kim, Director


Mr. John Kim – Mr. Kim is an independent business consultant, investor, and director of both public and private companies and has extensive experience in capital markets. He is passionate about helping entrepreneurs grow their businesses, especially in the areas of technology and healthcare, and currently advises several startups in Canada. Mr. Kim is a director of WELL Health Technologies Corp, a TSX listed company, where he chairs the Compensation Committee. He is also a director of EMERGE Commerce Ltd., a TSX Venture listed company, where he chairs the Audit Committee. Previously, Mr. Kim was an award-winning Portfolio Manager whose career spanned over 20 years, managing mutual funds, hedge funds, and private client assets. Mr. Kim is a CFA charter holder and graduated from the University of Toronto with a B.Sc. in Applied Mathematics.

Brent Norton, Chairman


Dr. Brent Norton holds his medical doctorate degree from McGill University, an MBA from Ivey Business School at Western University and was granted the ICD.D designation by the Institute of Corporate Directors following the completion of the Directors Education Program at the Rotman School of Business in Toronto. With over 25 years of experience in the life sciences industry, Dr. Norton has used his cross-functional knowledge to develop strategy, raise capital and build important relationships in the academic and business community. Operationally, he has built R&D and commercial operations, led transactions with AstraZeneca, Eli Lilly, L’Oreal, Parke Davis/Pfizer and others, and taken products through the FDA to global out-licensing with Johnson & Johnson. His contributions to five companies have allowed early investors the opportunity to crystallize investment gains of over $2.5B. Brent is currently a Venture Partner with Lumira Ventures and has recently been appointed as a board member of the prestigious Association of Faculties of Medicine of Canada.

Dale Weil, Director


Ms. Dale Weil brings 40 years of business experience, the last 20 in healthcare. Most was acquired at McKesson Canada, a diversified healthcare company and the largest pharmaceutical distributor in the country. At McKesson Canada, Ms. Weil led various businesses in distribution, specialty pharmaceuticals, hospital solutions, strategy & business development, Retail Banner Management, and was most recently Senior Advisor to the President (until February 2018). She had the opportunity to oversee diverse sets of assets, contributing to growth through organic strategies, business development and M&A activity. She was named Executive Director of the Teresa Dellar Palliative Care Residence and Montreal Institute for Palliative Care in January 2020, having joined in 2018 to launch the Institute and where she had been involved as a board member since 2010. Ms. Weil holds a Bachelor's degree in Marine Biology and a Master's degree in Business Administration, both from McGill University. Additionally, Ms. Dale Weil received the ICD.D designation from the Institute of Corporate Directors having completed the Directors Education Program at McGill University. Ms. Weil is also a director of Thera-Technologies and the McGill Health University Centre. She is deeply committed to board work in health care and health sciences sectors and aspires to contribute through strategy & business development, M&A, and governance.